Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P

− On Track for Continued Topline Growth With Potential to Deliver Incremental Revenue by FY20251 Driven by its 14 Global Brands− Highly Diversified Pipeline of Approximately 40 Potential Therapies Expected to Drive Growth Beyond FY2025− Delivering on Financial Commitments, Including Strong Underlying Core Operating...

Related Keywords

Japan ,China ,Osaka ,United States ,Japanese ,Christophe Weber ,Christina Beckerman ,Adaptate Biotherapeutics ,Ryoko Matsumoto ,Exchange Commission ,International Financial Reporting Standards ,Takeda Pharmaceutical Company Limited ,International Media ,Takeda Pharmaceutical Company ,Continued Topline Growth With Potential ,Deliver Incremental Revenue ,Highly Diversified Pipeline ,Therapies Expected ,Drive Growth Beyond ,Financial Commitments ,Strong Cash Flow ,Healthcare Conference ,Chief Executive Officer ,Term Growth Expected ,Deliver Sustained ,Pharmaceutical Company Limited ,Rare Genetics ,Plasma Derived Therapies ,Annual Report ,Underlying Revenue ,Core Operating Profit ,Underlying Core Operating Profit ,Core Net Profit ,Underlying Core ,Net Debt ,Free Cash ,Regulatory Success ,